Could you review my asthma action plan and recommend appropriate stepwise therapy adjustments?

Asthma Action Plan Review and Stepwise Therapy Recommendations

All patients with asthma should have a written asthma action plan that specifies daily management and clear instructions for recognizing and responding to worsening symptoms, with therapy adjusted using a stepwise approach based on current asthma control rather than initial severity 1.

Core Components of an Effective Written Action Plan

Your asthma action plan must include these evidence-based elements 2:

Daily Management Zone (Green Zone)

• Specific daily controller medications with exact doses and frequency
• Environmental trigger avoidance strategies specific to your exposures
• Peak flow monitoring if you have moderate-severe asthma or history of severe exacerbations 1

Early Warning Zone (Yellow Zone)

Action points should be based on personal best peak flow (not % predicted) and include 2:

• 2-4 specific action points (most effective approach)
• When to increase inhaled corticosteroid (ICS) dose
• When to add short-acting beta-agonist (SABA) use
• Specific symptoms triggering action: increased cough, nighttime awakening, activity limitation

Medical Alert Zone (Red Zone)

• When to start oral corticosteroids (prednisolone 30-60 mg) 3
• Emergency contact numbers
• When to call 911 or go to emergency department immediately

Critical evidence: Plans using personal best peak flow with 2-4 action points and recommending both ICS and oral corticosteroids consistently improve outcomes, while plans based on % predicted peak flow do not 2.

Stepwise Therapy Adjustment Algorithm

Step 1: Assess Current Control (Not Just Severity)

Evaluate these domains at every visit 1, 4:

Impairment Domain:

• Daytime symptoms: How many days/week?
• Nighttime awakenings: How many nights/week?
• SABA use for symptom relief: More than 2 days/week indicates poor control
• Activity limitation: Any interference with normal activities?
• Lung function: FEV1 or PEF (≥80% predicted = well controlled; <60% = very poorly controlled)

Risk Domain:

• Exacerbations requiring oral steroids in past year
• Emergency department visits or hospitalizations
• Progressive decline in lung function

Step 2: Determine Current Treatment Step

For patients ≥12 years 5, 6:

Step 1: As-needed SABA only (intermittent asthma)

Step 2: Low-dose ICS (preferred) OR leukotriene receptor antagonist (alternative)

Step 3:

• Preferred: Low-dose ICS + long-acting beta-agonist (LABA) OR medium-dose ICS
• Alternative: Low-dose ICS + leukotriene receptor antagonist

Step 4: Medium-dose ICS + LABA (preferred)

Step 5: High-dose ICS + LABA, consider omalizumab if allergic asthma

Step 6: High-dose ICS + LABA + oral corticosteroid, consider omalizumab

Step 3: Make Treatment Adjustments

Before stepping up therapy, ALWAYS verify 1, 4:

1. Medication adherence (most common cause of poor control)
2. Correct inhaler technique (demonstrate and have patient show you)
3. Environmental trigger control
4. Comorbid conditions (rhinosinusitis, GERD, obesity)

Step Up if:

• Using SABA >2 days/week for symptom relief
• Any nighttime awakenings
• Any activity limitation
• FEV1 or PEF <80% predicted
• ≥2 exacerbations requiring oral steroids in past year

Step Down if:

• Well controlled for at least 3 consecutive months 5, 6
• No nighttime symptoms
• SABA use ≤2 days/week
• Normal activity level
• FEV1 or PEF >80% predicted with <25% diurnal variability 3

Critical Pitfalls to Avoid

Never treat with SABA alone 7, 8: All adults and adolescents with asthma should receive ICS-containing medication. SABA monotherapy increases risk of severe exacerbations and death.

Don't skip ICS monotherapy inappropriately 9: Moving directly from no controller to ICS+LABA without documented inadequate response to ICS alone lacks evidence support, though may be appropriate for severe symptoms.

Recognize step-down opportunities 9: Episodic care focused on exacerbations misses opportunities to reduce medication burden. Schedule routine follow-up visits specifically to assess control and consider stepping down.

For severe asthma requiring Step 4+: Consider specialist referral 5, 4. Before adding oral corticosteroids at Step 6, trial high-dose ICS + LABA + leukotriene receptor antagonist 5.

Special Considerations for Treatment Selection

At Step 3 1, 6:

• Adding LABA to low-dose ICS more consistently improves symptoms (impairment domain) than increasing ICS dose
• Increasing ICS dose may better reduce exacerbation risk but requires 4-fold increase
• Balance rare risk of life-threatening exacerbations with LABA against individual patient priorities

Monitoring frequency 1:

• Every 1-6 weeks while gaining control
• Every 1-6 months once controlled (depending on step)
• Every 3 months if considering step-down

All patients need quick-relief medication: SABA as needed for all steps, with frequency of use serving as control indicator 5.